Press Releases | Alaunos

Date	Title and Summary	Additional Formats
Jun 29, 2026	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes,
May 26, 2026	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice A non-confidential investor presentation
May 18, 2026	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models Findings from non-GLP DIO mouse studies show effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology findings consistent with lower hepatic steatosis FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc.
Mar 02, 2026	Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice Efforts to conduct